Pharmacological Treatments for Bipolar Disorder: An Update

2001 ◽  
Vol 6 (1) ◽  
pp. 7-11
Author(s):  
Vivek Kusumakar ◽  
Stan P. Kutcher
Keyword(s):  
Bipolar Disorder ◽  
Pharmacological Treatments

scholarly journals The capacity of schizophrenia and bipolar disorder individuals to make autonomous decisions about pharmacological treatments for their illness in real life: A scoping review

2020 ◽  
Vol 3 (3) ◽  
Author(s):  
Enric Vincens Pons ◽  
Luis Salvador‐Carulla ◽  
Alfredo Calcedo‐Barba ◽  
Silvia Paz ◽  
Thomas Messer ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Scoping Review ◽  
Real Life ◽  
Pharmacological Treatments

Psychopharmacological Treatments for Bipolar Disorder

2020 ◽  
pp. 191-232
Author(s):  
Stephen M. Strakowski ◽  
Jorge R. C. Almeida ◽  
Melissa P. DelBello
Keyword(s):  
Bipolar Disorder ◽  
Treatment Options ◽  
Mood States ◽  
Acute Mania ◽  
Evidence Based ◽  
Pharmacological Treatments ◽  
Bipolar Illness ◽  
The Past ◽  
Psychiatric Conditions ◽  
Third Line

The discovery of lithium in 1946 led to a revolution in the management of bipolar disorder as well as other psychiatric conditions. Since that time and especially in the past 20 years, treatment options for bipolar disorder have progressively advanced such that a modern practitioner has a number of evidence-based options to manage the illness. However, the evidence is strongest in adults for acute mania and weakens in other mood states and in youth. Nonetheless, based on the available evidence, this chapter provides recommendations for first-, second-, and third-line pharmacological treatments for bipolar illness to guide clinicians. Additionally, specific considerations for the various medications are reviewed. Suggestions are provided for both adults and youth.

The management of treatment-resistant bipolar disorder

2017 ◽  
Author(s):  
Salih Selek ◽  
Ives Cavalcante Passos ◽  
Jair C. Soares
Keyword(s):  
Bipolar Disorder ◽  
Treatment Resistance ◽  
Pole Position ◽  
Short Description ◽  
Evidence Based ◽  
Pharmacological Treatments ◽  
Mixed States ◽  
Treatment Resistant ◽  
Future Directions ◽  
Depressive Episodes

Treatment-resistant bipolar disorder is a challenging area in clinical psychiatry and both defining treatment resistance and managing it is difficult despite new emerging pharmacological and non-pharmacological treatments. This chapter revisits the definition in treatment resistance in bipolar and summarizes the general recommendations in treatment-resistant bipolar disorder by taking revision of the guidelines to ‘pole position’. Manic and depressive episodes are covered in different subtitles. A short description of the complementary and alternative treatments is also mentioned. Special conditions in treatment resistance including co-morbidities, mixed states, and substance abuse are discussed separately. Future directions are also addressed by both evidence-based and naturalistic findings. Final recommendations for mania and depression are discussed after each subtitle and illustrated with a figure to give readers a visual summary.

scholarly journals Na+, K+-ATPase Signaling and Bipolar Disorder

2018 ◽  
Vol 19 (8) ◽  
pp. 2314 ◽  
Author(s):  
David Lichtstein ◽  
Asher Ilani ◽  
Haim Rosen ◽  
Noa Horesh ◽  
Shiv Singh ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Mental Illness ◽  
Drug Development ◽  
Neuronal Activity ◽  
Intracellular Signaling ◽  
Depressive Disorders ◽  
Chronic Mental Illness ◽  
Pharmacological Treatments ◽  
Cellular Processes ◽  
Endogenous Regulators

Bipolar disorder (BD) is a severe and common chronic mental illness characterized by recurrent mood swings between depression and mania. The biological basis of the disease is poorly understood and its treatment is unsatisfactory. Although in past decades the “monoamine hypothesis” has dominated our understanding of both the pathophysiology of depressive disorders and the action of pharmacological treatments, recent studies focus on the involvement of additional neurotransmitters/neuromodulators systems and cellular processes in BD. Here, evidence for the participation of Na+, K+-ATPase and its endogenous regulators, the endogenous cardiac steroids (ECS), in the etiology of BD is reviewed. Proof for the involvement of brain Na+, K+-ATPase and ECS in behavior is summarized and it is hypothesized that ECS-Na+, K+-ATPase-induced activation of intracellular signaling participates in the mechanisms underlying BD. We propose that the activation of ERK, AKT, and NFκB, resulting from ECS-Na+, K+-ATPase interaction, modifies neuronal activity and neurotransmission which, in turn, participate in the regulation of behavior and BD. These observations suggest Na+, K+-ATPase-mediated signaling is a potential target for drug development for the treatment of BD.

Sign in / Sign up

Export Citation Format

Share Document